There are a considerable number of biopharmaceuticals that have been approved for clinical use in the past decade. Over half of these new generation drugs are glycoproteins, such as monoclonal antibodies or other recombinant glycoproteins, which are mostly produced in mammalian cell lines. The linked carbohydrate moieties affect not only their physicochemical properties and thermal stability but also crucial features like receptor-binding activity, circulating half-life, as well as immunogenicity. The structural diversity of these attached glycans can be manifested in altered monosaccharide composition and linkages/positions among the monosaccharide building blocks. In addition, as more and more biosimilar products hit the market, understanding the effects of their glycosylation modifi cation has become a recent target in effi cacy and safety issues. To ensure consistent quality of these products, glycosylation profi les have to be monitored and controlled in all steps of the manufacturing process, i.e., from clone selection to lot release. In this paper, we describe some of the recently introduced and commonly used sample preparation techniques for capillary electrophoresis (CE)-based profi ling and structural elucidation of N-glycans. The presented protocols include protein A affi nity partitioning of monoclonal antibodies (mAbs), enzymatic release of the N-linked glycans, labeling of the liberated carbohydrates, reaction mixture purifi cation techniques to remove the excess labeling reagent, and high-resolution and rapid capillary electrophoresis-laser-induced fl uorescence (CE-LIF)-based profi ling of the labeled and purifi ed N-glycans.
Introduction
Glycosylation is one of the most important and complex posttranslational modifi cations on the majority of new biotherapeutic drugs. Glycoproteins are typically produced as mixtures of different glycoforms having the same polypeptide backbone but differing in glycosylation site specifi city (macroheterogeneity) and in the structures at a same site (microheterogeneity) [ 1 ] . It is well known that these attached carbohydrate chains are very important from the point of view of quality by design (QbD) in biopharmaceutical manufacturing because of their signifi cant infl uence on activity and effi cacy. Since glycan biosynthesis and processing are exquisitely responsive to the host cell type and growth environment, changes may occur in the glycosylation profi le of different production batches of the innovative drug but also in their follow-up versions (biosimilars) [ 2 ] . Meanwhile, there have been reports of adverse events caused by nonhuman glycosylation moieties due to the presence of immunogenic residues, such as α-1,3-Gal or N-glycolylneuraminic acid [ 3 ] . Therefore, it is crucial to maintain the carbohydrate distribution profi le of glycosylated biopharmaceuticals for effi cient and safe use [ 4 , 5 ] . Advances are continually being made in the biotechnology industry to minimize glycan heterogeneity and improve the sensitivity and specifi city of the analytical assays used to identify and quantify possible glycosylation changes. In spite of the fact that several analytical techniques and assays have already been implemented and validated for the characterization of these complex molecules, rapid and comprehensive profi ling and quantitation of all glycoforms are still a challenging task. One of the most powerful bioseparation techniques for detailed N-linked glycosylation analysis of biotherapeutics is capillary electrophoresis combined with laser-induced fl uorescent (CE-LIF) detection [ 6 -10 ] . Different CE-based assays can be used to characterize the drug during the manufacturing process, troubleshoot production problems, and demonstrate biosimilarity or comparability.
In this protocol, we introduce some of the most effi cient sample preparation methods for CE-LIF analysis of complex carbohydrates. Usual protocols start with affi nity partitioning of the formulated or crude monoclonal antibody product using protein A resins. This step is essential for the complete removal of all additives and formulation ingredients, which can affect glycan labeling or the consequent CE-LIF analysis. Next, we describe some of the commonly used in-solution N-glycan release method using peptide-N-glycosidase F (PNGase F). The affi nity partitioning and glycan release steps are followed by fl uorophore labeling of the liberated glycans and the removal of the excess labeling material. Finally, we describe the optimal capillary electrophoresis analysis parameters for the labeled N-linked glycans in respect to regular profi ling (high resolution) and rapid screening (low resolution).
Materials
Always use HPLC grade or ultrapure water (18 MΩ cm at 25 °C) for all solutions and buffers in all procedures. In addition, all reagents should be microbiology or HPLC grade unless otherwise stated. The use of powder-free, nitrile gloves for all sample handling procedures is important too. Ensure that all glass, plasticware, and solvents are free of glycosidases and possible environmental carbohydrate contaminations. All procedures should be performed using appropriate personal safety protection, laboratory coat, eyeglasses, and nitrile gloves. The labeling reactions should be performed in a fume hood. 7. 100 mM sodium carbonate buffer (pH 9.0) to replace the neutralization buffer.
8. 20 mM sodium carbonate buffer, pH 7.0.
9. 10 % acetic acid in water to replace the enrichment buffer.
10. 10 kDa cutoff spin fi lters (Nanosep 10k Omega, Pall, Port Washington, NY, USA).
11. Microcentrifuge equipped with a rotor suitable for 2.0-mL microfuge tubes and capable to provide 17,200 × g .
12.
Centrifugal vacuum evaporator (e.g., SpeedVac).
1. 50 mM dithiothreitol (DTT) in water.
2. 50 mM iodoacetamide (IAM) in water.
3. 20 mM NaHCO 3 , pH 7.0.
4. Peptide-N-glycosidase F (ProZyme, Hayward, CA, USA).
5. 0.2-mL fl at cap PCR tubes.
6. PCR thermocycler or other general microvial-based heating devices capable to provide stable 65 and 37 °C temperature.
7. 15 % acetic acid in water. 
Protein

1 M sodium cyanoborohydride in tetrahydrofuran (THF).
10. 10 mg/mL APTS solution in 15 % acetic acid.
11. 10 kDa cutoff spin fi lters (Nanosep 10 k Omega, Pall, Port Washington, NY, USA).
12. Microcentrifuge equipped with a rotor suitable for 2.0-mL microfuge tubes and capable to provide 17,200 × g .
13. Centrifugal vacuum evaporator.
14. Vortex mixer.
15. Pipettors and disposable pipette tips (P5/P10, P200, and P1000).
16. Miscellaneous labware for buffers and dilutions.
1. 1000+ PhyTip normal phase columns with 20 μL bed volume.
2. Rainin multichannel 100-1000-μL pipettor (8 channels).
3. Acetonitrile (100 %, HPLC grade).
4. 20 % acetonitrile in water.
5. 95 % acetonitrile in water.
6. 96-deep-well plate 2 mL/well.
7. Centrifugal vacuum evaporator.
8. 0.2-mL fl at cap PCR tubes.
GlykoPrep Digestion Module (ProZyme) includes:
• Digestion (RX) cartridges (24 cartridges).
• Immobilization reagent set.
• Denaturation reagent.
• Blocking reagent.
• Digestion reagent set.
• N-Glycanase.
• 25× digestion buffer.
• Finishing reagent.
• Aluminum sealing fi lm.
GlykoPrep APTS Cleanup Module (ProZyme) includes:
• 5× APTS sample loading buffer.
• Cleanup (CU) cartridges (24 cartridges).
3. Acetonitrile (HPLC grade).
4. Microcentrifuge (capable of 50-1,000 × g ) and rotor suitable for 1.5-/2.0-mL microcentrifuge vials.
5. Heater and heating block accommodating 0.2-mL PCR tubes.
6. Centrifugal vacuum evaporator.
APTS Cleanup
Using 1000+ PhyTip with 20 μL Normal Phase Resin
Sample Preparation Using GlykoPrep Rapid N-Glycan Preparation Platform
7. Vortex mixer.
8. Pipettors and disposable pipette tips (P5/P10, P200, and P1000).
9. Miscellaneous labware for buffers and dilutions.
1. Beckman Coulter PA 800 plus Pharmaceutical Analysis System, equipped with LIF detection (solid-state 488-nm laser) and 32 Karat software v.8.0 or higher.
2. Carbohydrate separation buffer (Beckman Coulter).
3. N-CHO-coated capillary, 50 μm ID (Beckman Coulter).
4. Sample vials.
5. 2.0-mL plastic vials.
6. Vial caps.
7. Capillary cartridge equipped with N-CHO-coated capillary with a total length of 60.2 cm (effective length 50.2 cm).
Methods
1. Dilute the crude or formulated mAb sample to 2 mg/mL using the PBS buffer, pH 7.2 ( see Note 1 ).
2. Transfer 220 μL of capture buffer to the fi rst row of the 96-well plate. 9. Purifi cation (third and fourth row): pass 100 μL of protein A wash buffer I through the resin bed in one cycle at a fl ow rate of 250 μL/min followed by a second wash with 200 μL wash buffer II, passing through the resin bed in one cycle at a fl ow rate of 250 μL/min. It is essential to use wash buffer II as it exchanges the pH 7.4 buffer of wash buffer I and in doing so ensures effective low pH elution during the enrichment step.
10. Enrichment (fi fth row): elute the captured IgG with 15 μL 10 % acetic acid solution (pH ~2.5) passed through the resin bed in four cycles at a fl ow rate of 100 μL/min. Neutralize the sample by the addition of 175 μL of 100 mM sodium carbonate buffer (pH 9.0). 14. The desalted proteins are recovered from the membrane by inversion of the cartridge-to a new tube-and centrifugation at 1,320 × g for 4 min ( see Note 3 ).
CE-LIF
15. To increase the recovery, invert the cartridge again-back to the original position-pipette 50 μL of water onto the membrane, vortex it for 1 min, invert the cartridge, and centrifuge at 1,320 × g for 4 min. Repeat this step two times ( see Note 4 ).
16. After the desalting step, dry the recovered mAb sample in the centrifugal vacuum evaporator (heat setting turned to the off position) using continuous vacuum.
1. Dissolve the dry protein samples in 45 μL of 20 mM sodium carbonate buffer, pH 7.0.
2. Add 5 μL of 50 mM dithiothreitol (DTT) to the sample and incubate at 65 °C for 15 min.
3. After the incubation step, add 5 μL of 50 mM iodoacetamide (IAM) to the sample and keep in the dark for 10 min at room temperature (RT).
4. Add 2 μL 2.5 U/mL of N-glycanase solution to the sample and incubate for 2 h to overnight at 37 °C. 9. Dry the clean released glycans in a centrifugal vacuum evaporator (heat setting turned to off position).
1. Dissolve the dry protein sample in 50 μL of 20 mM sodium carbonate buffer, pH 7.0.
2. Add 50 μL of denaturation reagent to the protein solution.
Mix well by pipetting up and down several times.
3. Incubate at room temperature for at least 5 min.
4. Nest the cartridge in a 0.5-mL screw cap microtube.
In-Solution N-Glycan Release
N-Glycan Release Using GlykoPrep Digestion (RX) Cartridges
5. Pipette 50 μL of 100 % acetonitrile into the sample cup of the RX cartridge.
6. Place the tube in a centrifuge and spin at 300 × g for 3 min.
7. Pipette 150 μL of denaturation reagent into the sample cup of each cartridge.
8. Spin at 1,000 × g for 2 min.
9. Empty the fl ow through by lifting each RX cartridge and removing the liquid collected in the microtube below. Dispose off this liquid and return the cartridge to the tube.
10. Load 100 μL of the denatured mAb sample into the sample cup of each RX cartridge.
11. Spin at 50 × g until all sample cups are empty (~15 min).
12. Empty the fl ow through as described in step 9 .
13. Pipette 50 μL of blocking reagent into the sample cup of each RX cartridge.
14. Spin at 300 × g for 3 min.
15. Pipette 50 μL of digestion buffer (1× concentrated) into the sample cup of each RX cartridge.
16. Spin at 300 × g for 3 min.
17. Prepare the digestion and elution assembly by nesting each PCR tube into 0.5-mL tubes and nesting that within a 2.0-mL microcentrifuge tube.
18. Transfer the RX cartridge into the corresponding digestion and elution assemblies and return to the centrifuge. Dispose the microtubes and the fl ow through.
19. Pipette 10 μL of enzyme solution (2.5 μL of N-glycanase and 7.5 μL of 1× digestion buffer) into the sample cup of the RX cartridge.
20. Spin at 300 × g for 3 min; do not discard the fl ow through.
21. Transfer the PCR tubes with the RX cartridges to a 45 °C PCR heat block and incubate for 30 min.
22. Remove the PCR tubes with RX cartridges from the heat block and return to the digestion and elution assembly.
23. Pipette 15 μL of fi nishing reagent into the sample cup of each RX cartridge.
24. Spin at 300 × g for 3 min.
25. Remove RX cartridge from the PCR tube. The eluted N-glycans are now in the PCR tubes; do not discard.
26. Open the PCR tubes, return them to the digestion assembly (minus the RX cartridge), and dry the N-glycans in a centrifugal vacuum evaporator (heat setting turned to the off position) for 30 min or until fully dry.
1. Add 4 μL of 10 mg/mL APTS (in 15 % acetic acid) to the dried sugars.
2. Add 2 μL of 1 M NaBH 3 CN (in THF) to the sample ( see Note 6 ).
3. Incubate the reaction mixture at 37 °C overnight. For nonsialylated glycoproteins, incubation at 55 °C for 2 h is suffi cient.
1. Add 100 μL of water to the labeled samples and mix it by pipetting up and down several times. Transfer the mixture to the third row of the plate (Fig. 1 ) and add 900 μL acetonitrile to it. Mix the sample well again.
2. Prepare the elution (20 % acetonitrile in water) and the washing solutions (95 % acetonitrile in water) and fi ll up the 96-deep-well plate as shown in Fig. 1 ( see Note 7 ).
3. Insert the 1000+ DPA-6S normal phase PhyTip columns (20 μL bed volume) to the multichannel pipettor.
4. Perform conditioning in the fi rst row (Fig. 1 ) by passing 900 μL of elution solution through the resin bed four times.
5. Equilibrate the columns by passing 900 μL of washing solution over the resin bed for four times in the second row in Fig. 1 . 6. Load the labeled glycans to the columns by pipetting 900 μL of sample mixture through the resin bed ten times (Fig. 1 , third row).
7. Wash off the salts and excess labeling reagent by pipetting 900 μL of washing solution through the resin bed ten times. Repeat this step six times, always using fresh solution in a new row (Fig. 1 , fourth to ninth row).
8. Elute the APTS-labeled glycans by passing 180 μL elution solution through the resin bed three times. Repeat this step in the next two rows (Fig. 1 , 10th to 12th row).
9. Collect the eluted sample from the elution positions to a 2.0-mL tube and dry it in a centrifugal vacuum evaporator (heat setting turned to the off position).
10. Dissolve the dried samples in 25 μL HPCE grade water and proceed to capillary electrophoresis analysis.
1. Prepare 5 mL of APTS sample load buffer by adding 1 mL of 5× APTS sample load buffer to a small, glass graduated cylinder. Bring the volume up to 5 mL with 100 % acetonitrile. 5. Spin at 300 × g for 3 min or until the sample cup of each CU cartridge is empty.
6. Discard the fl ow through and spin at 300 × g for 3 min again.
7. Pipette 200 μL of APTS sample load buffer into the sample cup of each CU cartridge.
8. Spin at 300 × g for 3 min.
9. Discard the fl ow through and repeat steps 6 and 7 again.
10. Place the CU cartridge to a clean 0.2-mL PCR tube and nest this back to the 2.0-mL microcentrifuge tube, which is already containing the 0.5-mL tube.
11. Pipette 25-50 μL of ultrapure water into the sample cup of each CU cartridge.
12. Spin at 1,000 × g for 3 min. The PCR tube now contains the purifi ed labeled N-glycans; do not discard.
13. N-Glycan samples are now ready for capillary electrophoresis analysis. If not analyzed immediately, store sealed at −20 °C in the dark. 5. Autozero at 1.0 min.
Cleanup of the FluorophoreLabeled Glycans by APTS Cleanup Modules
6. End at 5.0 min.
7. An example of a rapid CE-LIF analysis of APTS-labeled IgG N-glycans performed on 10 cm separation length is shown in Fig. 3 with the corresponding glycan structures of the peaks.
Notes
1. If the sample concentration is less than 2 mg/mL, preconcentrate before starting the procedure.
2. Make sure that all the liquid passed through the membrane after the last step. If not, spin it again.
3. Never use higher g -forces for the inverted cartridge as it can destroy the membrane.
4. When vortexing, always hold the fi ltration device vertically.
5. Do not discard the fl ow through because it contains the released N-glycans.
6. Always work with NaBH 3 CN in the fume hood! 7. Always prepare fresh acetonitrile solutions. 
